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Abstract
Background: Previously, we demonstrated up-regulated activated CD4+ and CD8+ T lymphocytes as well as up-
regulated cytotoxic NK cells in the blood of patients with idiopathic recurrent miscarriage. In the present study, we
tried to identify deficiencies in counter-regulating immune mechanisms of these patients.
Method: Cytokines were determined in NK cells and in plasma samples of 35 healthy controls, 33 patients with
idiopathic recurrent miscarriage, 34 patients with end stage renal disease, 10 transplant patients early and 37
transplant patients late post-transplant using flow-cytometry and luminex. In addition, cytokines were studied in
supernatants of cell cultures with peripheral blood mononuclear cells stimulated in-vitro with tumor cell line K562.
Results: Patients with idiopathic recurrent miscarriage exhibited the highest absolute cell counts of circulating
TGFß1+ NK, NKT and T lymphocytes and the lowest TGFß1 plasma levels of all study groups (for all p < 0.050). In-
vitro, peripheral blood mononuclear cells of patients with idiopathic recurrent miscarriage showed high
spontaneous TGFß1 production that could not be further increased by stimulation with K562, indicating increased
consumption of TGFß1 by activated cells in the cell culture. Moreover, patients with idiopathic recurrent miscarriage
had abnormally high IL4+ as well as abnormally high IFNy+ NK cells (p < 0.010) but similar IL10+ NK cell numbers
as female healthy controls and showed the lowest plasma levels of IL10, TGFß3, IL1RA, IL1ß, IL5, IL6, IL8, IL17, TNFα,
GM-CSF, TPO and VEGF and the highest plasma levels of G-CSF, FGF-basic, CCL3 and CXCL5 as compared to female
HC and female transplant recipients (for all p < 0.050).
Conclusions: Patients with idiopathic recurrent miscarriage show an activated immune system that can hardly be
stimulated further and cannot be efficiently down-regulated by up-regulated TGFß1+ and IL4+ NK, NKT and T
lymphocytes which are present concomitantly in these patients. The strongly decreased TGFß and IL10 plasma
levels indicate deficient down-regulation and reflect a dysbalance of the immune system in patients with idiopathic
recurrent miscarriage. These findings may be relevant for explaining the pathogenesis of idiopathic recurrent
miscarriage.
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Background
Recurrent loss of pregnancy is an important reproduct-
ive health issue, affecting 2–5% of couples [1]. Almost
half of the cases remain unexplained and are treated em-
pirically, using progesterone supplementation, anticoa-
gulation, and/or immunomodulatory approaches [1].
Immunological causes, such as immunological rejection
or development of an intrauterine micromilieu that is
harmful for fetus and pregnancy, are suspected reasons
for idiopathic recurrent miscarriage (iRM) [2, 3]. In pre-
vious studies, we were able to show highly elevated uter-
ine NK cells in iRM compared to non-iRM patients [4].
Furthermore, compared with female healthy controls
(HC), iRM patients showed higher counts of circulating
activated CD4+ and CD8+ T cells [5] and cytotoxic NK
cells [6] and lower levels of circulating presumably im-
munoregulatory IL10 + CD56bright NK cells [6]. In con-
trast, renal transplant recipients with functioning grafts
late post-transplant exhibited lower cytotoxic and higher
IL10 + CD56bright NK cell counts than HC [6]. More-
over, in transplant recipients with good long-term graft
outcome, high cytotoxic NK cells were associated with
impaired graft outcome whereas high immunoregulatory
IL10 + CD56bright NK cells were associated with good
long-term graft function. We speculate that these find-
ings on cytotoxic and immunoregulatory IL10 +
CD56bright NK cells might have relevance for the fetal
allograft in pregnant women. Because women with idio-
pathic RM showed high cytotoxic and low immunoregu-
latory IL10 + CD56bright NK cells in the circulation, we
concluded that the immune system of iRM patients is
dysbalanced and that this might favor
immunologically-induced abortion. Mor et al. postulated
that the first trimester of pregnancy is associated with
inflammation, which is required for blastocyst implant-
ation [3]. The second trimester is characterized by an
anti-inflammatory and T helper 2 (TH2)-type immune
microenvironment that is necessary for fetal growth, and
in the third trimester there is a switch to an inflamma-
tory and TH1-type immune state, which is necessary for
labor and delivery [3]. We hypothesize that iRM patients
exhibit a continued inflammatory immune response dur-
ing the second trimester that cannot be
counter-regulated by increasing inhibitory immune
mechanisms, which eventually results in an unfavorable
intrauterine micromilieu that is harmful for the fetus
and results in the loss of pregnancy.
We compared iRM patients with female HC as well as a
series of HC including males to identify abnormally in-
creased or decreased cell subsets and cytokine levels
in-vivo and in-vitro. Additionally, iRM patients were com-
pared with dialysis patients and transplant recipients late
post-transplant. All transplant recipients received low
dose immunosuppression and were free of infection or
rejection. As shown in our previous publication, this
group consists of patients with down-regulated cytotoxic
effector mechanisms and up-regulated counter-regulating
immunoregulatory mechanisms forming an immune sys-
tem in balance [7]. While immunosuppressive drugs in-
hibit the formation of cytokines and cytokine receptors,
cells that already express certain cytokines and cytokine
receptors act similar in patients with or without immuno-
suppressive drug treatment. We hypothesize that the com-
parison of iRM patients with kidney recipients late
post-transplant represents a comparison of patients with
an unbalanced to patients with a balanced immune sys-
tem. Immune mechanisms that are associated with good
or poor graft outcome in transplant recipients might also
be associated with successful or unsuccessful pregnancy of
the semi-allogeneic fetus.
In the present study, we looked for indications for a
dysregulation of IL4, IL10 and TGFß induced
counter-regulating inhibitory immune mechanisms. We
investigated IL4+, IL10+, TGFß+ and IFNy+ NK, NKT
and T cells in the blood of HC, iRM and transplant pa-
tients and compared intracellular cytokine production
with cytokine levels measured in plasma. In addition, we
stimulated NK cells in PBMC cultures using the tumor
cell line K562 as stimulator and measured cytokine ex-
pression in NK cells before and after stimulation and in
the supernatants of the in-vitro stimulated cells. We
speculated that cells with T cell receptor interact with
HLA on allogeneic cells whereas NK cells without T cell
receptor might react with cells missing or expressing
particular HLA class I antigens (inhibiting or activating
KIRs) or cells expressing stress-induced MICA and
MICB (ligand NKG2D) and/or HLA-E (ligand NKG2A)
on the cell surface [8].
Results
We studied 33 iRM patients, 35 HC (19 female), 34
ESRD patients (15 female), 10 renal transplant recipients
early (3 female) and 37 renal transplant recipients late
(14 female) post-transplant. Results of females are de-
tailed in the text whereas findings of both males and fe-
males are depicted in the figures of the Additional files
1, 2, and 3. Gating strategy is shown in Fig. 1.
Intracellular cytokine production of blood NK, NKT and T
cells
iRM patients showed higher absolute numbers of circu-
lating NK, NKT and T lymphocytes producing IL4 and
TGFß1 and higher absolute numbers of NK and NKT
cells with IFNy production than female HC (for all p <
0.050) (Fig. 2 a +b). Moreover, iRM patients had higher
absolute counts of IL4+ NK and NKT cells than female
ESRD patients (p < 0.050), higher TGFß+ NK cells than
female patients late post-transplant and higher TGFß+
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and IFNy+ NKT and T cells than female ESRD patients
and female transplant recipients late post-transplant (for
all p < 0.050) (Fig. 2 a+b). IL10+ NK, NKT and T cells
were similar in all groups with the exception of higher
absolute IL10+ NK cell counts in female transplant
recipients early post-transplant and higher IL10+ NKT
cells in female ESRD patients compared to iRM patients
(for all p < 0.050) (Fig. 2 a+b).
When, in addition, iRM patients were compared with
male and female HC and male and female ESRD and
Fig. 1 Gating strategy for the determination of NK, NKT and T cell subsets. After excluding doublets from the total of acquired events, peripheral
blood lymphocytes (PBL) were gated according to FSC/SSC and CD45/SSC dot plot. Then, CD3-CD56+ NK cells, CD3 + CD56+ NKT cells and CD3+
T cells were gated in the CD3-APC/CD56-PerCPCy5.5 dot plot. CD3-CD56+ NK cells were further analyzed according to the intensity of the CD56
and CD16 expression (CD16-V450/CD56-PerCPCy5.5 dot plot). Further, dependent on isotype controls, subsets of NKT cells, T cells,
CD56brightCD16dim/− NK cells, CD56dimCD16+ NK cells and CD56 + HLADR+ NK cells were analyzed using the depicted gate settings in dot
plots of IL10R/TGFßRII, cIFNy/cIL10, cTGFß/cIL4. FSC, forward-scattered light, SSC, side-scattered light
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transplant patients (Additional file 1: Figure S1a + b),
iRM patients showed higher absolute counts of IL4+,
TGFß+ and IFNy+ NK, NKT and T cells than male and
female HC, ESRD patients and patients late
post-transplant (p < 0.050). Moreover, iRM patients had
higher absolute numbers of IL10+ NKT cells than male
and female ESRD patients and male and female kidney
transplant recipients early and late post-transplant (for
Fig. 2 a+b IL4+, TGFß1+, IL10+ and IFNy+ NK, NKT and T cell counts in peripheral blood. iRM patients showed higher absolute numbers of NK,
NKT and T cells producing IL4 and TGFß1 than female HC, higher absolute numbers of IFNy+ NK and NKT cells than female HC and higher IL4+
and TGFß1+ NK and TGFß1+ and IFNy+ NKT and T cells than female kidney transplant recipients late post-transplant (for all p < 0.050) whereas
IL10+ NK cells were similar in all transplant patient groups and female HC (a, b, c and d). Similar trends were observed for the proportions of IL4
+ T cells, TGFß1+ NKT cells and IFNy+ NK and NKT lymphocytes (p < 0.050). Nineteen female HC, 15 female ESRD, 14 female renal transplant
recipients late and 3 early post-transplant and 33 iRM patients were studied. Data are given as median ± interquartile range
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all p < 0.050) (Additional file 1: Figure S1a + b). When, in
addition, relative cell numbers were analyzed, iRM pa-
tients showed significantly higher proportions of IL4+,
TGFß+ and IFNy+ NK, NKT and T cells and of IL10+
NK cells than male and female HC (for all p < 0.050)
(Additional file 1: Figure S1a + b). The similar trends of
relative and absolute cell numbers suggest a strong
up-regulation of cell subsets with immunosuppressive
(IL4 and TGFß) as well as immunostimulatory (IFNy)
phenotype in iRM patients compared to female HC and
female transplant recipients.
Cytokine receptors on blood NK, NKT and T cells
An up-regulation of cytokine receptors, measured as
relative increase of cytokine receptor positive cells, sig-
nals a strong need for paracrine produced cytokines. NK
cells of iRM patients showed lower expression of IL4R,
TGFßR and IL10R (for all p < 0.050) but similar expres-
sion of IFNyR compared to NK cells of female transplant
recipients late post-transplant. Conversely, iRM patients
had the highest absolute counts of IFNyR+ NK cells
among all female patients and female HC (p < 0.050)
while absolute cell counts of IL4R+, TGFßR+ and IL10R
+ NK cells were similar in RM patients, female HC, fe-
male ESRD patients and female transplant recipients late
post-transplant (for all p > 0.050). The data suggest a low
need for paracrine produced IL4, IL10 and TGFß and a
strong need and consumption of auto- and paracrine pro-
duced IFNy in RM patients (Fig. 3) (Additional file 2: Fig-
ure S2) to maintain the strong IFNy-dependent cytotoxic
potential in RM patients, as published previously [6].
Cytokine levels in plasma
Plasma levels of IL4, TGFß1, IFNy and IL10 in the different
patient groups were inverse to absolute counts of IL4+,
TGFß1+, IFNy+ and IL10+ cell subsets in the peripheral
blood. Plasma levels were lowest in iRM patients but high-
est in female transplant recipients (Fig. 4 a+b). iRM patients
showed the lowest TGFß1 and IL10 plasma levels when
compared to female HC, female ESRD patients and female
transplant recipients early and late post-transplant, lower
IL4 plasma levels than female transplant recipients late
post-transplant and female ESRD patients and lower
plasma IFNy than female ESRD patients (for all p < 0.050)
(Fig. 4 a+b). In contrast, female transplant recipients late
post-transplant showed higher IL4, TGFß1 and IL10 (for all
p < 0.050) but similar IFNy plasma levels as female HC (p >
0.050). In addition, iRM patients showed the lowest plasma
levels of the pro-inflammatory/ inflammatory cytokines
TNFα, IL1ß, IL6, IL17 and GM-CSF, of anti-inflammatory
IL-1RA and TGFß3 and of the cytokines IL5, IL8, TPO and
VEGF compared to female HC and female transplant
Fig. 3 a-d IL4R+, TGFßR+, IFNyR+ and IL10R+ NK cells in peripheral blood. iRM patients had lower relative counts of IL4R+, TGFßR+ and IL10R+
and higher absolute numbers of IFNyR+ NK cells than female kidney graft recipients late post-transplant (for all p < 0.050). Moreover, iRM patients
showed the highest absolute counts of IFNyR+ NK cells of all examined groups (for all p < 0.050). The data suggest a lower expression of IL4R,
TGFßR and IL10R on NK cells of iRM patients but an increased response of IFNyR+ NK cells compared to female transplant recipients. Nineteen
female HC, 15 female ESRD, 14 female renal transplant recipients late and 3 early post-transplant and 33 iRM patients were studied. Data are
given as median ± interquartile range
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recipients late post-transplant (for all p < 0.050) (Fig. 4 a
+b). They had also lower levels of the chemokines CCL5/
RANTES than female HC and of CCL4/MIP1ß than fe-
male ESRD and female transplant recipients late
post-transplant (for all p < 0.050) (Fig. 4 a+b). Conversely,
iRM patients showed the highest plasma levels of G-CSF,
FGF-basic, CCL3/MIP1α as well as CXCL5 compared to
female HC and female transplant recipients late
post-transplant (for all p < 0.050) (Fig. 4 a+b). Interest-
ingly, plasma IFNy, TGFß2, IL1α, IL2, IL12 and CCL2/
MCP-1 were similar in iRM patients, female HC and fe-
male transplant recipients late post-transplant (p > 0.050)
(Fig. 4 a+b). Similar results were observed when plasma
cytokine levels of iRM patients were compared with those
Fig. 4 a+b Plasma levels of cytokines and chemokines. iRM patients showed the lowest plasma levels of the pro-inflammatory/ inflammatory
cytokines TNFα, IL1ß, IL6, IL17 and GM-CSF, of anti-inflammatory IL1RA, IL10, TGFß1 and TGFß3 and of the cytokines IL5, IL8, VEGF and TPO
compared to female HC and female transplant recipients late post-transplant (for all p < 0.050). They had also lower levels of the chemokines
CCL5/RANTES than female HC and of CCL4/MIP1ß than female ESRD and female transplant recipients late post-transplant (for all p < 0.050).
Conversely, iRM patients showed the highest plasma levels of G-CSF, FGF-basic and CCL3/MIP1α as well as very high plasma levels of CXCL5
compared to female HC and female transplant recipients late post-transplant (for all p < 0.050). Interestingly, plasma IFNy, TGFß2, IL1α, IL2, IL12
and CCL2/MCP-1 were similar in iRM patients, female HC and female transplant recipients late post-transplant (p > 0.050). Twenty-six female HC,
15 female ESRD, 4 female renal transplant recipients early and 15 female renal transplant recipients late post-transplant as well as 33 iRM patients
were studied. Data are given as median ± interquartile range
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of male and female transplant patients and HC (Add-
itional file 3 Figure S3a+b). In summary, the data show ab-
normally low plasma IL10, TGFß1, TNFα, IL1ß, IL1RA,
TPO and VEGF in iRM patients and abnormally high
levels of these cytokines, and in addition of IL4, in female
transplant recipients late post-transplant. The data suggest
a systemic down-regulation of anti-inflammatory cyto-
kines in iRM patients and a systemic up-regulation of
these cytokines in female transplant recipients late
post-transplant.
Because iRM patients showed abnormally high numbers
of blood cells producing anti-inflammatory cytokines in
the presence of abnormally low plasma levels of these cy-
tokines, we studied in cell cultures with PBMC whether
the production of anti-inflammatory cytokines can be in-
creased in NK cells using K562 cells as a NK cell-specific
stimulus, whether the stimulated NK cells were able to re-
lease these cytokines in the supernatant of the cell culture
and whether consumption of the secreted cytokines (by
activated NK cells) is increased in-vitro.
IL4, TGFß1, IL10 and IFNy in NK cells after stimulation
with K652 in-vitro
PBMC of 6 iRM patients, 8 kidney transplant recipients
> 3 months post-transplant, 3 kidney transplant
recipients < 3 months post-transplant, 4 ESRD patients
and 3 HC were incubated with tumor cell line K562
using an E:T ratio of 5:1. K562 stimulates particularly
NK cells and proportions of IL4+, TGFß1+, IL10+ and
IFNy+ NK cells were measured before and after stimula-
tion in the cell cultures. iRM patients and kidney trans-
plant recipients > 3months post-transplant showed an
increase of IFNy+ NK cells after stimulation, and the lat-
ter, in addition, an increase of IL4+ NK cells compared
to female HC (for all p < 0.050) (Fig. 5) suggesting that
in iRM and transplant patients IFNy production of NK
cells can be further increased by stimulation whereas
production of TGFß1 and IL10 appears to remain stable.
IL4, TGFß1, IL10 and IFNy in supernatants after
stimulation with K562 in-vitro
In-vitro studies were performed with cell suspensions of
7 HC, 9 iRM and 5 ESRD patients as well as 3 patients
early and 11 late post-transplant. NK cells were stimu-
lated in PBMC cultures with K562 using an E:T ratio of
5:1. IL4, TGFß1, IL10 and IFNy levels were analyzed in
supernatants obtained with and without stimulation.
The most interesting finding was that cells of iRM pa-
tients after incubation in medium showed the highest
spontaneous TGFß1 production of all female patients
Fig. 5 IL4+, TGFß1+, IL10+ and IFNy+ NK cells before and after stimulation with K562 in-vitro. PBMC of iRM patients, kidney transplant recipients
> 3 months post-transplant, kidney transplant recipients < 3 months post-transplant, ESRD patients and HC were incubated with tumor cell line
K562 using an E:T ratio of 5:1. K562 stimulates particularly NK cells. Proportions of IL4+, TGFß1+, IFNy+ and IL10+ NK cells were measured before
and after stimulation in the cell cultures. iRM patients and kidney transplant recipients > 3 months post-transplant showed an increase of IFNy+
NK cells after stimulation, the latter, in addition, an increase of IL4+ NK cells (for all p < 0.050). Number of patients tested for IFNy+ and IL10+ and
in brackets IL4+ and TGFß1+ NK cells: 3 (2) HC, 4 (4) ESRD, 3 (1) early and 8 (6) late post-transplant and 6 (4) iRM patients
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and HC (vs female transplant recipients late
post-transplant p = 0.080). After stimulation, there was a
trend that TGFß1 levels in the supernatants of iRM pa-
tients were lower than before stimulation indicating a
strong consumption of TGFß1 by activated NK cells. In
contrast, transplant recipients late post-transplant exhib-
ited TGFß1 levels in the supernatants that increased
during stimulation (p < 0.050) (Fig. 6 a+b). A similar
high spontaneous cytokine production and strong cyto-
kine consumption by activated cells was observed for
IL6 in the supernatants of iRM patients (iRM vs female
transplant recipients late post-transplant p = 0.068).
Similar to TGFß, IL6 levels decreased during stimulation
in cell cultures of iRM patients but increased in those of
transplant recipients late post-transplant (for all p <
0.050). Other cytokines in the supernatants showed simi-
lar production and consumption patterns in iRM pa-
tients, transplant recipients as well as HC (Fig. 6 a+b).
The data suggest that iRM patients have pre-activated
NK cells with strong spontaneous TGFß1 production in
the circulation that strongly consume TGFß1. The
strong TGFß1 consumption might contribute to the low
TGFß1 plasma levels in these patients.
Discussion
In a previous study we observed that, compared with fe-
male healthy controls, iRM patients possessed abnor-
mally high cytotoxic and abnormally low IL10 +
CD56bright NK cells in the peripheral blood, whereas
renal transplant recipients on low-dose immunosuppres-
sion late post-transplant exhibited abnormally low cyto-
toxic and abnormally high IL10 + CD56bright NK cell
counts [6]. Moreover, iRM patients showed higher abso-
lute numbers of NK cells with predominantly inhibitory
killer-cell immunoglobulin-like receptors (KIR) and
CD94/NKG2 receptors than female HC [8]. They exhib-
ited significantly increased levels of NK cells with inhibi-
tory CD158a, CD158b, CD158e, NKG2A and
stimulatory NKG2D receptors, whereas female ESRD pa-
tients had normal and female transplant recipients lower
or normal numbers of these cells compared to female
HC [8]. Interestingly, the phenotype CD158a+/CD158b
+/CD158e+/NKG2A+/NKG2D+ was more common in
iRM patients than in female HC and female transplant
recipients late post-transplant, supporting the hypothesis
that iRM patients have an abnormal up-regulation of in-
hibitory KIR and NKG2A receptors as well as of stimu-
latory NKG2D determinants [8]. We concluded that the
dysbalance of cytotoxic and potentially immunoregula-
tory NK cells in iRM patients might contribute to the
pathogenesis of iRM and that the balance of low cyto-
toxic and high IL10 + CD56bright NK cells in renal
transplant recipients might be favorable for good
long-term graft acceptance. In the present study, we
investigated additional NK cell subsets with presumable
immunoregulatory function in the blood of iRM and
transplant patients as well as HC, and we analyzed
whether these cells might affect the cytokine levels in
plasma and contribute to a systemic immunosuppressive
cytokine pattern.
Our data show that iRM patients have abnormally
high absolute cell counts of IL4+ and TGFß1+ NK, NKT
and T lymphocytes in the blood that show low IL4R and
TGFßR expression. These cells do not need paracrine
secreted IL4 and TGFß1 because of their own strong
production of these cytokines. Transplant recipients, in
contrast, have normal cell counts of IL4+ and TGFß1+
NK, NKT and T lymphocytes and abnormally high IL4
and TGFß1 plasma levels. Although iRM patients show
the highest numbers of IL4+ and TGFß1+ cell subsets in
the blood, they have the lowest levels of these cytokines
in plasma compared to HC and all patient groups. The
data suggest that NK, NKT and T lymphocyte counts do
not strongly correlate with plasma levels of IL4 and
TGFß1 and do not induce a systemic immunosuppres-
sive milieu in the circulation. Presumably, the peripher-
ally increased IL4+ and TGFß+ NK, NKT and T cells in
iRM patients originate from the uterus, however, they
are unable to establish a micromilieu in the uterus that
is protective for the fetus [9, 10].
The opposite holds true for IL10. In the present study,
summarizing IL10 + CD56bright and IL10 +
CD56dimCD16+ NK cells as IL10+ NK cells, there was
no difference in IL10+ NK cell numbers among iRM pa-
tients, female HC and female transplant recipients. In a
previous study, we reported on abnormally high IL10 +
CD56bright NK cells in transplant recipients and abnor-
mally low IL10 + CD56bright NK cells in iRM patients
[6] and these observations are paralleled by abnormally
low IL10 plasma levels in iRM patients and abnormally
high IL10 plasma levels in transplant recipients in the
present study. The data support the hypothesis that
plasma IL10 originates in part from IL10 + CD56bright
NK cells and that IL10 + CD56bright NK cells might
strongly contribute to systemic immunosuppression in
the circulation. Moreover, in the previous study we de-
scribed a striking association of IL10 + CD56bright NK
cell counts in the blood with graft function in renal
transplant recipients [6] suggesting that this NK cell
subset might be strongly immunoregulatory. In the same
study, CD8+ perforin+granzymeB+ NK cells, which can
be thought of as the opponent of IL10 + CD56bright NK
cells, were shown to be associated with impaired graft
outcome [6]. The combination of high IL10 +
CD56bright NK cell counts and high IL10 plasma levels
in transplant recipients with good long-term graft func-
tion supports the hypothesis that IL10+ NK cell subsets
might have a strong immunoregulatory role in transplant
Zhu et al. BMC Immunology           (2019) 20:10 Page 8 of 15
recipients. IL10+ NK cells that suppressed
antigen-specific T-cell responses were reported by Deniz
et al. [11] and others as summarized by Vivier et al. [12].
iRM patients, in contrast, show a deficit of this presum-
ably immunoregulatory subset in the circulation and we
assume that this deficit might contribute to the patho-
genesis of idiopathic RM. As summarized by Mor et al.
[3], a pro-inflammatory immune response supports im-
plantation and placentation of the blastocyte and initi-
ates pregnancy, followed by an anti-inflammatory stage
of fetal growth and a final pro-inflammatory switch for
labor and delivery. Our data suggest that patients with
idiopathic RM do not switch to an anti-inflammatory
stage.
Fig. 6 a + b Cytokine and chemokine levels in cell culture supernatants. PBMC of 9 iRM patients, 11 kidney transplant recipients > 3 months post-
transplant, 3 kidney transplant recipients < 3 months post-transplant, 5 ESRD patients and 7 HC were incubated with tumor cell line K562 using
an E:T ratio of 5:1. K562 stimulates particularly NK cells. Cytokine and chemokine levels were measured in the supernatants of unstimulated and
stimulated cell cultures. The most interesting finding was that cells of iRM patients showed the highest spontaneous TGFß1 production of all
female patients and HC after incubation in medium indicating a strong pre-activation of cells (iRM vs female transplant recipients late post-
transplant p = 0.080). After stimulation, TGFß1 levels were lower than before stimulation indicating a strong consumption of TGFß1 by activated
NK cells of iRM patients. In contrast, transplant recipients late post-transplant exhibited a higher TGFß1 production after than before stimulation
(p < 0.050). A similar high spontaneous production and strong consumption of cytokines by activated cells was observed for IL6 in the
supernatants of iRM patients (iRM vs female transplant recipients late post-transplant p = 0.068)
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In a previous study, we reported on abnormally high
activated CD3 + DR+, CD4 + DR+ and CD8 + DR+ T
lymphocytes in the circulation of patients with idio-
pathic RM [5]. When these pre-activated T lymphocytes
were stimulated in-vitro using phytohaemagglutinin,
pokeweed mitogen or anti-CD3 monoclonal antibody,
they showed decreased in-vitro proliferation compared
to lymphocytes of healthy female controls tested in par-
allel [5]. Similar results were obtained in the present
study for the production of TGFß1 in NK cells. Sepa-
rated peripheral blood lymphocytes of iRM patients
showed the highest spontaneous TGFß1 production of
all study groups as determined in cell culture superna-
tants. When NK cells were stimulated using tumor cell
line K562, TGFß1 levels in supernatants were lower after
stimulation than prior to stimulation, suggesting strong
spontaneous production of TGFß1 in circulating NK
cells that could not be increased by additional stimula-
tion in-vitro and decreased due to consumption by acti-
vated cells.
After abortion, patients with idiopathic RM have a
combination of abnormally high proportions of circulat-
ing pre-activated T lymphocytes, high cytotoxic NK cells
as well as high IL4+, TGFß1+ and IFNy+ NK cells and,
in addition, low proportions of circulating IL10 +
CD56bright NK cells, low plasma levels of IL4, IL10,
TGFß1 and TNFα and low proliferation of T lympho-
cytes stimulated polyclonally in-vitro. These findings
suggest the persistence of an inflammatory immune re-
sponse in patients with idiopathic RM that cannot be ef-
ficiently counter-regulated by up-regulated NK, NKT
and T cell subsets with an immunoregulatory phenotype.
The deficit of proliferation of T cells and TGFß1 produc-
tion of NK cells after in-vitro stimulation might be a
consequence of up-regulated immunosuppressive com-
ponents of the immune system, increased consumption
of cytokines in an autocrine manner by the activated im-
mune system of the patients, or beginning exhaustion of
pre-activated immune cells due to permanent activation
of these particular cell subsets. These factors might par-
tially explain the discrepancy between increased IL4+
and TGFß+ NK/NKT/T cells and decreased IL4 and
TGFß levels in the plasma of iRM patients.
Although stable transplant recipients have normal
counts of circulating IL4+ and TGFß+ NK, NKT and T
cells, they have abnormally high IL4 and TGFß1 plasma
levels suggesting that tissue resident NK, NKT and T
cells and/or other cell subsets produced those cytokines.
The higher plasma levels of these immunosuppressive
cytokines might contribute to immunoregulatory im-
mune mechanisms that allow the commonly practiced
stepwise tapering of immunosuppressive drug doses in
transplant recipients, eventually resulting in good
long-term graft function in the presence of minimal
doses of immunosuppressants. In contrast, iRM patients
showed normal or slightly decreased IL4 and TGFß1
plasma levels. Yue et al. reported on significantly higher
serum TGFß in the first trimester as compared to
non-pregnant women whereas serum IL10 was similar
in pregnant and non-pregnant women [13]. The same
authors observed increased serum levels of immunosup-
pressive IL35 in normal early pregnancy and decreased
levels in iRM patients [13]. Burns et al. reported on
higher IL1β, IL6, IL8, TNFα, IFNγ, IL10, and IL1 recep-
tor antagonist (IL-1RA) levels during late pregnancy in
amniotic fluid than in cord blood or maternal plasma
[14]. Decreased CCL5/RANTES plasma levels observed
by us and others [15] may contribute to iRM pathogen-
esis because it was shown in-vitro that RANTES sup-
presses alloantigen specific T-cell responses [15] and
promotes a pro-implantatory microenvironment that in-
fluences trophoblast cell survival and modulates the bal-
ance of maternal Treg/T effector lymphocytes in favor
of maternal tolerance [16, 17]. Our data are in line with
this observation and show low IL10, TGFß1, TNFα,
IL1ß, IL1RA, IL5, IL6, IL12, GM-CSF, VEGF and CCL5
in the plasma of iRM patients, in agreement with the ob-
servations of Burns et al. [14]. A limitation of our study
might be that a potential systemic increase of immuno-
suppressive cytokines was undetectable in our assays,
possibly because the iRM patients were at least 2 months
after the last pregnancy at the time of testing. The only
cytokine that was highest in iRM patients compared to
all other examined groups was G-CSF. Because G-CSF
plays an effective role in pregnancy success [18] the
strongly increased plasma levels may reflect a
counter-regulation to overcome the pathomechanisms of
iRM. Interestingly, G-CSF therapy is effective in redu-
cing pregnancy loss [19].
It should be further mentioned that iRM patients
showed higher Treg than female transplant recipients (p
= 0.037) and similar Treg numbers as female healthy indi-
viduals (p = 0.933), as also shown previously [6]. IL10+ T
cells were similar in all groups (iRM vs female transplant
recipients p = 0.923 and vs female HC p = 0.486) [6].
Down-regulation of the stimulated immune system
might be an option for balancing the immune system of
iRM patients. In a small clinical trial, 40 patients with
increased NK cells were treated with intralipid infusions
that should exert an anti-inflammatory effect on the
up-regulated immune system [20]. Our own preliminary
data showed that iRM patients with very high
pre-pregnancy peripheral NK lymphocyte counts did not
benefit from lipid infusions and probably need additional
(pre-pregnancy) medication [20]. In a recently published
study, Liu et al. reported results of low-dose immuno-
therapy in iRM patients and showed lower proportions
of TH1 cells and higher proportions of TH2 cells and
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Treg as well as higher TGFß1 serum levels after than be-
fore treatment [21]. Patients with immunotherapy
achieved significantly more frequently pregnancy than
untreated patients [21]. The role of immunotherapy in
clinical practice is discussed controversially [22]. In con-
sideration of live birth and abortion rates, treatment pro-
tocols using combinations of corticosteroid, low dose
aspirin, unfractionated heparin, G-CSF, low molecular
weight heparin and/or intravenous immunoglobulin ap-
pear to be effective treatment strategies [19]. Treatment
with immunomodulatory substances should downregu-
late cytotoxic alloresponses and should induce immune
mechanisms that establish a favorable micromilieu for
the fetus.
Finally, from the perspective of a transplantation im-
munologist, which some of the authors are, female
long-term transplant recipients and healthy females con-
stitute interesting control groups for comparison with
iRM patients. As detailed by Mor et al. [3], intervals with
inflammatory and intervals with anti-inflammatory im-
mune responses alternate during pregnancy. The first
pregnancy trimester is shaped by an inflammatory, the
second by an anti-inflammatory and the third again by
an inflammatory immune response. These alterations are
dynamic and there are phases in between showing both
types of immune response. A control group of females
with normal pregnancy would be rather heterogeneous
with respect to the dominating immune response in the
periphery depending on the time point of blood dona-
tion during pregnancy.
There is another aspect. According to our hypothesis,
iRM patients had rejected the allogeneic fetus immuno-
logically more than 3 times according to the definition
of iRM. All iRM patients were investigated at least 3
months and maximally 12 months after the last abortion.
One would think that the immune system of these fe-
male patients should be more comparable to the im-
mune system of a non-pregnant than to that of a
pregnant female. After abortion and antigen loss, the im-
mune system of iRM patients should have returned to a
resting state. However, as shown in this study and pub-
lished in a previous manuscript [6], iRM patients showed
an abnormally high cytotoxic NK cell response. We in-
terpret this extremely high cytotoxic response as a
long-term immune response against a persisting antigen
and speculate that this cytotoxic immune response is di-
rected towards fetal cells that persist in the iRM pa-
tients. Physiologically, immune responses stop when the
triggering antigen is eliminated. Transplant recipients
are facing a similar immunological challenge. They are
continuously stimulated by an allograft. In contrast to
the iRM patients, they show quiescence parameters of
the immune system that are similar to female healthy in-
dividuals, as reported in our publications. Patients with
good long-term graft function show normal cytotoxic
and normal immunoregulatory responses in the circula-
tion, which agrees with the notion that their immune
system is in balance. The low maintenance doses of im-
munosuppressive drugs would not be sufficient to pre-
vent acute graft rejection immediately post-transplant.
Obviously, transplant recipients develop post-transplant
immune mechanisms that facilitate the reduction of im-
munosuppressive drugs to a low maintenance level. The
low maintenance dose of immunosuppressants is able to
prevent rejection triggered by unspecific immune stimu-
lation, induced for example by infections. Infections are
able to trigger rejections by IFN increases and
up-regulation of donor MHC antigens on cells of the
transplant.
Female long-term transplant recipients and healthy fe-
males constitute interesting control groups for compari-
son with iRM patients. These control groups did not
show the strong cytotoxic and counter-regulating immu-
noregulatory responses found in iRM patients, which
supports the hypothesis that iRM patients, despite evi-
dence for ongoing immunoregulatory activity, are not
able to establish a low level balance of immunostimula-
tory (IFNy+ cells, plasma IFNy, TNFα, G-CSF, etc) and
immunosuppressive (IL4+ and TGFß+ cells, plasma IL4,
TGFß, IL10, etc.) mechanisms. We speculate that the
missing balance prevents successful pregnancy and that
immunosuppressive therapy might be an option to facili-
tate such a balance. Our conclusion is based on the ob-
servations obtained in female healthy controls and
female long-term transplant recipients with good graft
function. We feel that the observations in these individ-
uals offer an interesting view on iRM patients that would
not be obtained when iRM patients would be compared
with normal pregnant women who are known to show
heterogeneous immune reactions that depend on the
duration of pregnancy, as described by Mor et al. [3].
Conclusions
In summary, iRM patients show an activated immune
system that can hardly be stimulated further and cannot
be efficiently down-regulated by up-regulated TGFß1+
and IL4+ NK, NKT and T lymphocytes which are
present concomitantly in these patients. The low IL4
and TGFß1 and strongly decreased IL10 plasma levels
indicate deficient down-regulation and reflect a dysba-
lance of the immune system in iRM patients.
Methods
Patients and healthy controls
Healthy blood donors and laboratory staff served as con-
trols. Blood samples from iRM patients were obtained
during visits at the outpatient clinic of the Department
of Obstetrics and Gynecology, University Hospital
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Heidelberg. Blood samples from transplant patients were
obtained during regular visits in the outpatient clinics of
the university hospitals in Heidelberg and Giessen. Table
1 summarizes the demographic patient data. Transplant
recipients were treated with combinations of cyclospor-
ine, tacrolimus, steroids and mycophenolate mofetil.
iRM patients had a history of 3 or more consecutive
miscarriages and anatomical disorders, endocrinologic
dysfunctions, autoimmunologic disorders, deficiencies in
coagulation factors, inherited haemostatic changes, and
fetal and parental chromosomal disorders were excluded.
Patients were investigated at least 2 months after the last
miscarriage.
Lymphocyte and NK cell subsets
Determination of lymphocyte and NK cell subsets was
performed as previously described [6]. 150 μl of whole
blood and fluorochrome-labeled monoclonal antibodies
against CD45, CD16, CD56, CD3, and HLA-DR were
added to each tube whereas IL4R, TGFßRII, IL10R,
IFNyR and IgG-isotype controls were added only to cer-
tain tubes. Tubes were vortexed and incubated in the
Table 1 Demographic data of patients and healthy controls
HC (n = 35) Late post-Tx (n = 37) Early post-Tx
(n = 10)
ESRD (n = 34) iRM (n = 33)
Ages (years, median, SD) 44 (13) 55 (10) 58 (12) 52 (14) 34 (4)
Days post-transplant (median, range) – 1602 (95–3786) 54 (7–93) – –
Sex (n, %)
Female 19 (54%) 14 (38%) 3 (30%) 15 (44%) 33 (100%)
Male 16 (46%) 23 (62%) 7 (70%) 19 (56%) 0
End stage renal disease (n, %)
Chronic glomerulonephritis – 3 (8%) 2 (20%) 7 (21%) –
Diabetes – 3 (8%) 0 2 (6%) –
Hypertension/ischemic – 2 (5%) 1 (10%) 1 (3%) –
Nephrosclerosis – 2 (5%) 0 5 (15%) –
Polycystic – 10 (27%) 4 (40%) 7 (21%) –
IgA nephropathy – 6 (16%) 0 5 (15%) –
Others – 11 (30%) 3 (30%) 7 (21%) –
Graft No. (n, %)
First – 35 (95%) 9 (90%) – –
Second – 2 (5%) 1 (10%) – –
Donor (n, %)
Living – 26 (70%) 5 (50%) – –
Deceased – 11 (30%) 5 (50%) – –
Cold ischemia time (n, %)
< 3 h – 26 (70%) 6 (60%) – –
> 3 h – 11 (30%) 4 (40%) – –
Serum creatinine (n, %)
< 2mg/dl – 33 (89%) 8 (80%) – –
> 2mg/dl – 4 (11%) 2 (20%) 34 (100%) –
GFR (n, %)
< 35 ml/min – 3 (8%) 2 (20%) 34 (100%) –
35–50ml/min – 12 (32%) 8 (80%) – –
> 50ml/min – 22 (60%) 0 – –
HLA-ABDR mismatch > 3 (n, %) – 11 (30%) 4 (40%) – –
CMV IgG+ recipients (n, %) – 16 (43%) 8 (80%) – –
CMV IgG+ donors (n, %) – 18 (49%) 8 (80%) – –
Abbreviations: HC healthy control, late post-Tx recipients late post-transplant, early post-Tx recipients early post-transplant, ESRD end stage renal disease, iRM
idiopathic recurrent miscarriage
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dark at room temperature for 30 min. Then, 2 ml of Lyse
solution diluted 1:10 (BD Bioscience, Sunnyvale, CA,
USA) was added and tubes were vortexed again, incu-
bated at room temperature for 10 min and centrifuged at
1300 rpm for 8min. After 2 washes of cells with 2ml
PBS, cells were suspended in 300 μl PBS and analyzed
using a FACSCanto II triple-laser flow cytometer (BD
Bioscience).
When intracellular proteins were analyzed, cells were
permeabilized, in addition, by adding 500 μl of BD
Perm/Wash buffer II diluted 1:10 (BD Bioscience). Cells
were incubated for 10 min, 2 ml PBS was added, tubes
were vortexed, centrifuged at 1300 rpm for 8 min, super-
natant was removed and discarded and pellets were sus-
pended in 100 μl PBS. Antibody against IL4, IL10,
TGFß1 and IFNy was added and incubated for 30 min,
tubes were vortexed and cells were washed twice in PBS.
Samples were analyzed using eight-color fluorescence
and a FACSCanto II triple-laser flow cytometer (BD Bio-
sciences). At least 50,000 lymphocyte events were stud-
ied in the initial FSC/SSC dot plot (see gating strategy in
Fig. 1). Because cells were not stimulated for intracellu-
lar staining of cytokines, our data reflect the cytokine
production of NK, NKT and T cells in-vivo.
Preparation of peripheral blood mononuclear cells and
target cells before stimulation
Frozen PBMC were thawed as described previously [6].
Cell concentration was adjusted to 2 × 106 cells/ml. Cells
were stored overnight in an incubator at 37 °C and 5%
CO2 atmosphere. K562 cell line was incubated at 37 °C
and 5% CO2 and the culture medium was changed 24 h
before the stimulation experiment.
Six-hour multiple response assay
The multiple response assay was performed as described
previously [6]. In brief, PBMC and K562 tumor cells
were adjusted to 2 × 106 cells/ml and 150 μl of PBMC
were incubated with 30 μl of K562 tumor cells at 37 °C
for 6 h using an E:T ratio of 5:1. After 1 h incubation
time, 20 μl of cell culture medium supplemented with
Monensin (Golgistop, BD Bioscience) diluted 1:100 was
added. Then cells were incubated for 5 h, centrifuged at
300 g for 5 min, suspended in 100 μl PBS, stained with
fluorochrome-labeled monoclonal antibody CD3, CD56,
CD16, CD45, and HLA-DR and incubated for 30 min at
room temperature in the dark. Cells were washed and
permeabilized using BD Perm/Wash buffer II (BD Bio-
science). Monoclonal antibody against TGFß1, IL4, IL10
or IFNy were added, samples were incubated for 30 min
at room temperature in the dark, washed with
permeabilization washing buffer and suspended in 300 μl
PBS. Fluorescence of cells was analyzed using an
eight-color fluorescence flow cytometer FACS Canto II
(BD Biosciences).
Determination of cytokines and chemokines in plasma
and supernatants
IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12 p70,
GM-CSF, IFN-γ, TNF-α and VEGF (Luminex Perform-
ance Assay, Human High Sensitivity Cytokine Base Kit
A; R&D systems, Wiesbaden, Germany), CCL2/MCP-1,
CCL3/MIP-1α, CCL4/MIP-1ß, CCL5/Rantes, CXCL5/
ENA-78, FGF basic, G-CSF and Thrombopoietin/TPO
(Human Luminex Performance Assay Base Kit, Panel A;
R&D systems, Wiesbaden, Germany) and TGFß1,
TGFß2 and TGFß3 (Luminex Performance Assay 3-plex
Kit; R&D systems, Wiesbaden, Germany) were deter-
mined in plasma and supernatants according to instruc-
tions of the manufacturer and analyzed using the
Luminex LX100 system (Luminex B.V., Het Zuiderkruis
1, 5215 MV ‘s-Hertogenbosch, The Netherlands).
Statistical analysis
PASW Statistics program version 21 (IBM, Chicago, Illi-
nois, USA), Wilcoxon signed rank test and
Mann-Whitney U test were used for statistical analysis.
With respect of the interpretation of the test results,
lymphocyte subsets were devided into cells with either
immunostimulatory (IFNy+, etc.) or immunoregulatory
phenotype (IL4+, IL10+, TGFß+, etc.) showing a trend
whether the immune system is stimulated or immuno-
suppressed. Therefore, we did not adapt p-values ac-
cording to Bonferroni correction and considered a result
with a p-value of < 0.050 as significant.
Additional files
Additional file 1: Figure S1a + b. IL4+, TGFß+, IL10+ and IFNy+ NK,
NKT and T cell counts in peripheral blood. iRM patients showed higher
absolute numbers of circulating NK, NKT and T lymphocytes producing
IL4, TGFß1 and IFNy than male and female HC, ESRD and transplant
patients late post-transplant (for all p < 0.050) with the exception of IFNy
+ NK cells which were similar in iRM patients and male and female kid-
ney transplant recipients early post-transplant (p = n.s.). Absolute numbers
of IL10+ NK, NKT and T cells were similar in iRM patients and male and
female HC. Thirty-five HC, 34 ESRD, 37 renal transplant recipients late and
10 renal transplant recipients early post-transplant as well as 33 iRM pa-
tients were studied. Data are given as median ± interquartile range. (ZIP
1402 kb)
Additional file 2: Figure S2. IL4R+, TGFßR+, IFNyR+ and IL10R+ NK,
NKT and T cell counts in peripheral blood. NK cells of iRM patients
showed lower TGFßR expression than those of male and female
transplant recipients early and late post-transplant (for all p < 0.050). iRM
showed the highest absolute count of IFNyR+ NK cells of all examined
groups (for all p < 0.050), suggesting a low need for paracrine produced
TGFß and a strong response of IFNyR+ NK cells. Thirty-five HC, 34 ESRD,
37 renal transplant recipients late post-transplant and 10 renal transplant
recipients early post-transplant as well as 33 iRM patients were studied.
Data are given as median ± interquartile range. (DOCX 1032 kb)
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Additional file 3: Figure S3a + b. Plasma levels of cytokines and
chemokines. iRM patients showed the lowest plasma levels of TGFß1,
TGFß3, IL10, TNFα, IL1ß, IL6, IL8, IL17 and GM-CSF and the highest plasma
levels of G-CSF and CXCL5 of all examined groups (for all p < 0.050).
Moreover, they had normal levels of IL2, IL4, IL12, TPO and VEGF that
were lower than those in male and female ESRD and transplant recipients
early and late post-transplant (for all p < 0.050). IFNy, IL1α and TGFß2
plasma levels were similar in iRM patients, male and female HC and trans-
plant recipients (for all p > 0.050). Thirty-five HC, 34 ESRD, 37 renal trans-
plant recipients late and 10 renal transplant recipients early post-
transplant as well as 33 iRM patients were studied. Data are given as me-
dian ± interquartile range. (ZIP 2437 kb)
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